Equities

Kazia Therapeutics Ltd

KZIA:NAQ

Kazia Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3247
  • Today's Change-0.006 / -1.70%
  • Shares traded209.52k
  • 1 Year change-67.87%
  • Beta2.1132
Data delayed at least 15 minutes, as of Sep 20 2024 20:44 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of AUD
(except for per share items)
Fiscal data as of Jun 30 2023202320222021
ASSETS
Cash And Short Term Investments5.247.3628
Total Receivables, Net3.900.090.08
Total Inventory------
Prepaid expenses1.632.001.72
Other current assets, total------
Total current assets119.4529
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net171921
Long term investments------
Note receivable - long term0.047.306.69
Other long term assets--0--
Total assets283657
LIABILITIES
Accounts payable0.861.52--
Accrued expenses3.472.240.23
Notes payable/short-term debt1.801.840
Current portion long-term debt/capital leases------
Other current liabilities, total1.441.130.79
Total current liabilities7.576.735.95
Total long term debt000
Total debt1.801.840
Deferred income tax2.292.562.93
Minority interest------
Other liabilities, total6.188.3310
Total liabilities161819
SHAREHOLDERS EQUITY
Common stock978480
Additional paid-in capital------
Retained earnings (accumulated deficit)(85)(65)(43)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.74)(0.85)0.46
Total equity121838
Total liabilities & shareholders' equity283657
Total common shares outstanding228139132
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.